A list of commonly used measurement tools for psoriasis management and clinical trials.
General
A simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages to measure disease severity and quality of life.
To express the severity of psoriasis by measuring redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
PGA: Physician's Global Assessment
Physician's assessment of the severity of disease based on a scale from clear to very severe.
Self-administered, patient-reported outcome measure (PRO) to assess symptom severity in chronic, plaque psoriasis.
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version as well as The Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
A clinical outcome measure for the assessment of genital psoriasis severity that accounts for the erythematous clinical presentation of genital psoriasis
IPC does not endorse or accept any responsibility for the content of external websites.
congress coverage SID 2021 Read the psoriasis highlights from the SID 2021 congress learn more
Latest news INSIDE LOOK campaign raises awareness about plaque psoriasisJune 16, 2021Amgen and Otezla® (apremilast) have partnered with Allan Avendaño, makeup artist to Hollywood A-listers, for the INSIDE LOOK campaign to share his journey living with plaque psoriasis and the difficulties of being in his demanding role and dealing with a chronic skin condition. Dermavant submits New Drug Application to FDA for tapinarof cream for the treatment plaque psoriasisJune 09, 2021Dermavant Sciences announced on June 3, 2021 that it has submitted a New Drug Application to the U.S. Food and Drug Administration for tapinarof for the treatment of mild, moderate and severe plaque psoriasis in adult patients. IPC International Fellow wins first prize for 2021 RADLA Poster PresentationJune 09, 20212019 IPC Fellow Romina Contreras was recognized at the 2021 Virtual RADLA Congress, winning first prize for her poster presentation. New data from the PsoProtect RegistryJune 01, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,118 cases. More News